Abstract:The incidence of heart failure (HF) is increasing year by year, second only to cancer. Paraoxonase 2 (PON2) plays a protective role in cardiovascular diseases, but the role of PON2 in HF has not been reported so far. In this study, we concluded that PON2 can ameliorate Ang II‐induced cardiomyocyte injury by targeting the Calnexin (CANX)/NOX4 signaling pathway. Background The incidence of heart failure (HF) presents an escalating trend annually, second only to cancer. Few literatures are available regarding on the role of paraoxonase 2 (PON2) in HF so far despite the protective role of PON2 in cardiovascular diseases. Methods PON2 expression in AC16 cells was examined with reverse transcriptase‐quantitative polymerase chain reaction and western blot following angiotensin II (Ang II) challenging. After PON2 elevation, 2, 7‐dichlorofluorescein diacetate assay estimated reactive oxygen species content, related kits appraised oxidative stress, enzyme‐linked immunosorbent assay evaluated inflammatory levels, and Western blot was applied to the analysis of apoptosis levels. Research on cytoskeleton was conducted by immunofluorescence (IF), and Western blot analysis of the expressions of hypertrophy‐related proteins was performed. BioGRID and GeneMania databases were used to analyze the relationship between PON2 and Calnexin (CANX), which was corroborated by co‐immunoprecipitation experiment. Subsequently, PON2 and CANX were simultaneously overexpressed in AC16 cells induced by Ang II to further figure out the mechanism. Results PON2 expression was depleted in Ang II‐induced AC16 cells. PON2 might mediate CANX/NOX4 signaling to inhibit oxidation, inflammatory, hypertrophy, and damage in Ang II‐induced AC16 cells. Conclusion PON2 can ease Ang II‐induced cardiomyocyte injury via targeting CANX/NOX4 signaling.

Congestive Heart Failure and Paraoxonase

Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development

[Association Between Paraoxonase Concentration and Risk of Acute Coronary Syndrome].

The changes of serum cytokine levels in lung infected patients suffered from heart failure

Kinetic monitoring of paraoxonase(PON) and its preliminary clinical application

The Molecular Bases of Anti-Oxidative and Anti-Inflammatory Properties of Paraoxonase 1

Changes and Significance of TNF-α,NOS Activity and NO in the Plasma of Patients with Chronic Congestic Heart Failure

PON2 ameliorates Ang II‐induced cardiomyocyte injury by targeting the CANX/NOX4 signaling pathway

Association of Serum Paraoxonase/Arylesterase Activity with All-Cause Mortality in Maintenance Hemodialysis Patients.

Protective Effect of Paraoxonase 1 of High‐density Lipoprotein in Type 2 Diabetic Patients with Nephropathy

Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?

Paraoxonase 1 Ameliorates Renal Lipotoxicity by Activating Lipophagy and Inhibiting Pyroptosis

Abstract 16746: Serum Paraoxonase Activity is a Better Predictor of Mortality Than Serum HDL Cholesterol Level in Patients on Maintenance Hemodialysis

The Association of the Cholesterol Efflux Capacity with the Paraoxonase 1 Q192R Genotype and the Paraoxonase Activity

Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Low Serum Paraoxonase1 Activity Levels Predict Coronary Artery Disease Severity

Paraoxonase 1 Q192R genotype and activity affect homocysteine thiolactone levels in humans

Exploring the Relationship between Canine Paraoxonase-1 (PON-1) Serum Activity and Liver Disease Classified by Clinico-Pathological Evaluation

Human paraoxonase gene cluster overexpression alleviates angiotensin II-induced cardiac hypertrophy in mice

Plasma Paraoxonase-1, Oxidized Low-Density Lipoprotein and Lipid Peroxidation Levels in Gout Patients

Paraoxonase I Activity and Its Relationship with Nutrition in Amyotrophic Lateral Sclerosis